Dendritic cells (DC) perform an important role in the initiation of the immune response through the local secretion of inflammatory mediators within diseased tissue in response to Toll-like receptor (TLR) ligation. However, DC vaccine strategies fail to make use of this capability against cancer. To harness the TLR response capability of DC against cancer, we tested a series of recombinant genes for their ability to redirect DC function specifically against a tumor-associated antigen. Each gene encoded a cell surface chimeric protein made up of extracellular single-chain immunoglobulin anti-erbB2 linked to an intracellular TLR-signaling component composed of either myeloid differentiation factor 88, interleukin-1 receptor-associated kinase-1 (IRAK-1) or the cytoplasmic domain of TLR4. Each gene was expressed in the DC line, JAWS II, to a similar degree following retroviral transduction. However, only the chimera containing IRAK-1 was able to mediate interleukin-12 and tumor necrosis factor-a secretion. Since TLR engagement can also activate DC and enhance their ability to stimulate T cells, we ligated the chimeric anti-erbB2-IRAK-1 receptor and determined the effect on the stimulation of T cells. We found that JAWS II cells triggered through chimeric anti-erbB2-IRAK-1 displayed an enhanced ability to stimulate ovalbumin-specific OT-II CD4 þ T cells. This first description of the generation of tumorreactive DC may lead to the development of new cell-based vaccines that can act at both the tumor site to induce danger and at the lymph node to stimulate a specific T-cell response.
Introduction
Vaccines are an attractive form of cancer treatment with potential to be cheaply and easily applied. A number of cancer vaccine formulations are currently under study, including protein or peptides, virus and dendritic cell based. [1] [2] [3] Vaccines aim to induce an effective immune response against tumor-associated antigens. Indeed, immune responses can be elicited by vaccines against some TAA, particularly in melanoma, as demonstrated by increased levels of circulating antigen-specific T cells, which can sometimes approach 50% of total circulating CD8 þ T cells. 4 However, to date, there have been few complete clinical responses mediated by cancer vaccines. 5 An important issue with respect to an effective immune response is the ability of antigen-specific T cells to traffic to tumor sites. 6 In addition, the tumor microenvironment has to be conducive to immune cell function. 7 In normal immune responses to microorganisms, appropriate signals (danger signals) are produced that result in the localized production of chemokines and cytokines. 8 Instrumental in this process are resident dendritic cells (DC) that respond to ligation of Toll-like receptors (TLR) by pathogen-associated molecular patterns present on microbial products. 9, 10 Eleven TLR are presently known to be specific for individual microbial products, including lipopolysaccharide (LPS) and unmethylated oligodeoxynucleotides (CpG). 11 Ligation of TLR by microbial products leads to a signaling cascade resulting in cellular activation and cytokine secretion. 12, 13 For example, ligation of TLR-4 by LPS in conjunction with the molecules CD14 and myeloid differentiation-2 (MD-2) results in signal transmission through myeloid differentiation factor 88 (MyD88), IL-1 receptor-associated kinase (IRAK) and tumor necrosis factor (TNF) receptor-associated factor-6 (TRAF6) leading to activation of two distinct pathways involving Jun N-terminal kinase (JNK) and nuclear factor-kb (NF-kb). The functional end result of signal transmission is cytokine production (interleukin-1 (IL-1), IL-12, TNF-a and others), chemokine production (macrophage chemotactic protein-1 (MCP-1), regulated upon activation normal T cell expressed and secreted, RANTES and others), upregulation of costimulatory molecules (CD80/86) and nitric oxide production. [13] [14] [15] [16] Thus, triggering through TLR leads to the release of pro-inflammatory cytokines while also priming DCs for efficient antigen presentation. The inflammatory environment so produced leads to enhanced chemokine production and upregulation of adhesion molecules on endothelium, which enables leukocyte recruitment.
Methods to induce danger signals within tumor include the direct intratumoural injection of TLR agonists, or expression of inflammatory cytokines by tumor cells. Some antitumor effects have been observed using these strategies, [17] [18] [19] [20] but it is not feasible to treat most patients in this manner. In addition, effective distribution of TLR agonists throughout the entire tumor mass is generally not feasible using simple injection at one site. What is needed is a danger-inducing reagent that can be administered systemically, but which penetrates tumor evenly and only acts locally within tumor. DC naturally penetrate most tissues of the body, including tumors, 21, 22 where they act as sentinels whose role is to detect danger and respond by secretion of inflammatory mediators and relay of antigen to lymphoid tissue for presentation to cells of the adaptive immune system. 23 It may be possible to use DCs as initiators of danger signals within tumor if they can be programmed to respond specifically to tumor.
In this study, we produced an entirely novel cell type, tumor-specific DCs, by genetic engineering, such that TLR signaling pathways are triggered in a tumor antigendependent manner. This was achieved through gene modification of a mouse DC cell line in vitro with a gene encoding a chimeric TLR composed of extracellular single-chain anti-erbB2 antibody linked to intracellular IRAK-1 (a-erbB2-IRAK-1). In this way DCs may trigger an inflammatory response in an antigen-dependent manner. ErbB2 is a cell surface growth factor receptor overexpressed on 30% of breast and ovarian cancers, but other single-chain antibody specificities exist with which it should be possible to target almost 100% of malignancies. [24] [25] [26] [27] [28] [29] [30] The immunotherapeutic application of this approach would involve the introduction of tumor-specific DCs into tumor-bearing hosts either alone to stimulate endogenous immune elements, or in combination with vaccines or adoptively transferred T cells that provide an enhanced number of antigen-specific T cells.
Materials and methods

Cell lines and culture
The JAWS II DC-like cell line and B16 melanoma, both derived from C57BL/6 mice, were obtained from the American Type Culture Collection (ATCC, Manassas, VA). The B16-erbB2 cell line, expressing cell surface human erbB2, was generated by transduction of B16 with the mouse stem cell virus (MSCV) retroviral vector encoding erbB2. The erbB2-expressing cell line was selected after fluorescence-activated cell sorting on cells expressing green fluorescent protein (GFP) also included in the vector. All cells were cultured in Dulbecco's modified Eagle's medium (DMEM, Gibco, Grand Island, NY) supplemented with 10% fetal calf serum, 2 mM glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin.
Chimeric receptor construction and retroviral vector production DNA encoding IRAK-1, MyD88 or transmembrane and cytoplasmic TLR4 (amino acids 629-835) was amplified by PCR of C57BL/6 spleen cDNA. The amplified DNAs were ligated into the previously described anti-erbB2-CD28-z chimeric construct, 26 as depicted in Figure 1 , which was incorporated into the retroviral expression plasmid, CLNCX. 31 The TLR4 transmembrane domain was retained in that construct since CD14 association with TLR4 is necessary for optimal function, 32 and transmembrane domains can be involved in molecular associations.
VSV-pseudotyped retroviral vector was produced from 293gp cells as described previously. 31 Briefly, plasmids containing the chimeric receptor and the vesicular stomatitis virus (VSV) envelope were transfected into 293gp cells (30 mg of each per 10 7 cells) using Lipofectamine 2000 according to manufacturer's instructions (Invitrogen, Carlsbad, CA). Following replenishment of media 24 h later, supernatant containing retroviral vector was harvested after a further 24 h and used to transduce JAWS II cells using 8 mg/ml polybrene and centrifugation at 1000 g for 1 hr/RT.
Cytokine secretion assays JAWS II cell lines were incubated with tumor cells in 1 ml of supplemented DMEM in 12-well tissue culture plates (5 Â 10 5 of each cell type per well). After overnight culture at 371C/10% CO 2 , supernatants were harvested and cytokine levels determined using enzyme-linked Figure 1 Schematic representation of the gene constructs. Each construct was composed of an extracellular domain consisting of the variable heavy (V H ) and variable light (V L ) regions of anti-erbB2 antibody joined by a linker, (Ser 1 Gly 4 ) Â 3. A 10-amino-acid section of c-myc (myc) was included as a tag epitope to enable detection using a c-myc-specific monoclonal antibody, which was followed by the hinge region of CD8. The transmembrane region (TM) was derived from either TLR4 or CD28, and the cytoplasmic domain was made up of either IRAK-1, MyD88 or the cytoplasmic region of TLR4. IRAK-1, IL-1 receptor-associated kinase; MyD88, myeloid differentiation factor 88; TLR4, Toll-like receptor-4. . Following a further two washes, cells were analyzed on a FACScalibur flow cytometer (Becton Dickinson). Detection of erbB2 and c-myc-tag was achieved using the primary antibody followed by a phycoerythrin (PE)-conjugated sheep antimouse immunoglobulin secondary antibody, with two washes in PBS/BSA after each step.
T-cell stimulation assays
For T-cell stimulation assays, JAWS II cell lines were first treated with either anti-c-myc, or LPS, or media alone for 48 h. The cells were then washed two times in media, and incubated in 1 mg/ml ovalbumin peptide 323-339 for 2 h/ 371C followed by two washes. These cells were then Hthymidine was added per well, and wells harvested using a cell harvester. Proliferation of CD4 þ T cells was determined by measuring the amount of 3 Hthymidine incorporated into DNA using a beta emission counter.
Results
Gene-modified JAWS II express chimeric a-erbB2 receptors JAWS II is an immortalized DC-like cell line derived from the bone marrow of p53À/À mice. 33 It was demonstrated to express cell surface markers typical of immature DC both before (Figures 2a-j) and after (Figures 2k-t) genetic modification. JAWS II was also demonstrated to secrete the cytokines IL-12 and TNF-a in response to TLR ligation by LPS in a dose-dependent manner (Figures 2u  and v) . This cell line was therefore considered suitable to use as a model to determine if DC could be engineered to respond specifically against a tumor-associated antigen in a TLR-like manner.
The TLR4 signaling pathway was chosen in this study since signaling in response to its ligand, LPS, is well characterized. Ligation of TLR4 has been previously demonstrated to result in signal transmission via MyD88 and IRAK-1, which results in DC activation and secretion of IL-12 and TNF-a. 12 To determine the optimal format for linking tumor antigen recognition to TLR signaling, a series of recombinant genes were constructed linking an erbB2-specific single-chain antibody alternately to the intracellular signaling domains of TLR4 or MyD88 or IRAK-1 (Figure 1) . JAWS II cells were transduced using VSV-pseudotyped retroviral vectors encoding the chimeric a-erbB2 receptors or control GFP. Expression of chimeric a-erbB2 receptors was demonstrated using flow cytometry following staining for the c-myc tag epitope incorporated into the chimeric receptor design (Figures  3a-c) . Specificity of staining for c-myc was evident from the lack of staining of non-transduced JAWS II. A control gene-modified JAWS II cell line was also generated by transduction with a retroviral vector encoding GFP. Transduction of this cell line was evident from the observed expression of GFP when subjected to flow-cytometric analysis (Figure 3d ).
JAWS II cells secrete cytokines in response to chimeric a-erbB2-IRAK-1 ligation TLR-mediated cytokine secretion is an important function of DC in response to pathogens, which results in inflammatory signals and T-cell activation. We therefore determined the response of the gene-modified JAWS II cells to chimeric receptor ligation. The JAWS II cell lines were exposed to immobilized anti-c-myc-tag antibody or LPS and the amount of IL-12 and TNF-a secreted determined by ELISA. All transduced and control JAWS II cell lines secreted both IL-12 and TNF-a in response to LPS, thereby demonstrating their ability to respond to signals via the TLR4 signaling pathway (Figures 4a and  b) , although the a-erbB2-MyD88-expressing cells had a lower capacity to secrete IL-12 than the other cell lines. However, only cells transduced with the anti-erbB2 chimera containing intracellular IRAK-1 (JAWS II-IRAK) secreted IL-12 and TNF-a in response to anti-cmyc-tag antibody (Figures 4a and b) , and this response was demonstrated to depend on the concentration of anti-c-myc-tag, with maximal stimulation at 5 mg/ml (Figures 4c and d) . Consequently, the remainder of the study focused on the a-erbB2-IRAK-1 chimeric receptor. Since upregulation of costimulatory molecules on DCs can also occur following TLR ligation, we determined whether JAWS II-IRAK cells could respond to a-erbB2-IRAK-1 ligation in a similar way. Indeed, following ligation of the chimeric receptor with anti-tag antibody JAWS II-IRAK cells upregulated CD86 expression to a similar degree as following exposure to LPS (Figures 4e-g ).
Having demonstrated that the JAWS II-IRAK cell line could respond to immobilized receptor-specific antibody, it was important to determine if encounter with erbB2 expressed on tumor cells could trigger a response. We generated an erbB2-expressing mouse melanoma cell line, B16-erbB2, by transduction with a retroviral vector containing the cDNA encoding human erbB2. Following (Figure 5a ), whereas the parental B16 did not express erbB2 (Figure 5b ). The level of erbB2 expression was similar to that observed on many human tumors (data not shown). JAWS II-IRAK cells were observed to secrete both IL-12 and TNF-a specifically in response to B16-erbB2 and not in response to B16 parental cells ( Figures  5c and d) . The requirement for a-erbB2-IRAK-1 receptor was evident from the lack of cytokine secretion by JAWS II-GFP.
Increased T-cell stimulatory capacity of JAWS II mediated by a-erbB2-IRAK-1 Upon ligation of endogenous TLR, DCs assume a more activated state, and acquire an increased ability to stimulate T cells. 34, 35 To determine if ligation of chimeric a-erbB2-IRAK-1 was able to mimic these capabilities, we exposed JAWS II-IRAK-1 cells to immobilized anti-c-myc antibody and analyzed the effect on the proliferation of OT-II T cells (specific for ovalbumin (OVA)) in response to OVA peptide-pulsed JAWS II-IRAK-1 cells. Both non-transduced and a-erbB2-IRAK-1-transduced JAWS II cells acquired increased T-cell stimulatory capacity following incubation with LPS ( Figure 6 ), which acts through endogenous TLR4, although non-transduced JAWS II cells had a lower capacity to stimulate T cells than transduced cells. Similarly, a-erbB2-IRAK-1-transduced JAWS II cells demonstrated increased T-cell stimulatory capacity following ligation of the chimeric receptor using immobilized anti-c-myc-tag antibody ( Figure 6 ). This increased capacity was specific for the a-erbB2-IRAK-1 receptor, since T-cell stimulation by non-transduced JAWS II cells did not increase following incubation with anti-c-myc-tag antibody. It is likely that this effect was also antigen-specific, although confirmation of this would require the use of JAWSII cells pulsed with other peptides. 
Discussion
Reasoning that DC responding specifically against tumor, in a manner similar to that against pathogens, might be better able to induce an antitumor immune response, we tested the principle that triggering TLR by TAA would induce tumor-specific activation of DC. In this study, we used JAWS II cells as a model of primary DC, because of their phenotype, which closely resembles that of blood or lymph node-derived myeloid DCs (CD11b   hi   CD11c med B220 À ), and because of their ease of culture and transduction. JAWS II served in this proof of principle study of the potential to redirect DC function by genetic manipulation of the TLR pathways.
We found that a chimeric gene linking erbB2 recognition to IRAK-1 signaling was able to mediate cytokine secretion similar to that observed in response to LPS. In addition, the chimeric gene was able to endow JAWS II cells with an increased ability to stimulate T cells. A series of chimeric receptors containing signaling domains from one of three alternate TLR pathway molecules were produced, but only the chimera containing IRAK-1 was found to be active. The reasons for this are not clear, but may include steric hindrance of important domains in TLR4 or MyD88 due to their incorporation into a chimeric molecule, rendering them incapable of interaction with downstream components of the TLR-signaling pathway.
Interestingly, the chimeric receptor-mediated response against tumor was less than the response to LPS or immobilized anti-c-myc tag antibody. This was most likely due to differences in ligand density or affinity, but may have also involved tumor-derived inhibitory factors that could downregulate the DC response.
Having demonstrated that the TLR response could be redirected against tumor antigen in a model in vitro system, the next logical step is to determine if this can be achieved using primary DC. A crucial requirement of this approach is for at least a proportion of injected DC to reach tumor where antigen is present for the non-major histocompatibility complex (MHC)-restricted interaction with the chimeric receptor. Freshly generated DC might be expected to retain reasonably natural trafficking abilities, which we did not consider possible with the long-term cultured JAWS II cell line. Indeed, preliminary experiments have demonstrated the ability of a proportion The clinical translation of this approach would involve injection of gene modified autologous DC either directly intratumorally or systemically, which may then trigger danger signals within the tumor. This may result in tumor antigen uptake by DC, followed by their movement to lymph nodes and stimulation of specific T cells. The processed antigen need not be the same as that used to trigger the TLR pathway; rather it could be any antigen whether that be a shared self antigen, differentiation antigen, cancer-testes antigen or neo-antigen. Thus, these gene-modified DC could serve as a vaccine in their own right that does not rely on knowledge of all potential antigens. Alternatively, gene-modified DC could be used in combination with vaccines or adoptively transferred T cells, where they would serve purely as a means of creating danger signals within tumor to enable effective recruitment of immune effector cells.
Clearly, the immune system can respond powerfully against microorganisms, and TLR play an important part in this response. Further development of the concept described in this study may enable us to more closely approximate this degree of response against tumorassociated antigen, and may provide a novel effective form of cancer therapy.
